Efficacy of transcatheter arterial embolization plus targeted chemotherapy for advanced hepatocellular carcinoma: A case report and literature review

Table 3 Treatment-related adverse events graded according to CTCAE v5.0

Adverse event	CTCAE grade	Timing	Management	Outcome
Oxaliplatin hypersensitivity (generalized skin rash, nausea, retching)	Grade 2	Cycle 6	Anti-allergic and symptomatic treatment	Resolved
Elevated ALT (baseline 106 IU/L, peaked at 148 IU/L post-TAE, 130 IU/L during cycle 2)	Grade 1	Throughout treatment	Hepatoprotective therapy (glutathione, tiopronin, bicyclol, silymarin)	Normalized
Elevated AST (baseline 68 IU/L, peaked at 157 IU/L during cycle 2)	Grade 1	Throughout treatment	Hepatoprotective therapy	Normalized
Anlotinib-related adverse events (leukopenia, hypertension, hand-foot syndrome)	None	-	-	-

ALT: Alanine aminotransferase; AST: Aspartate transaminase; TAE: Transcatheter arterial embolization.